NewAmsterdam Pharma Company N.V.

The momentum for this stock is not very good. NewAmsterdam Pharma Company N.V. is not a good value stock. NewAmsterdam Pharma Company N.V. is not a good growth stock. NewAmsterdam Pharma Company N.V. is not very popular among insiders. NewAmsterdam Pharma Company N.V. is a mediocre stock to choose.
Log in to see more information.
NAMS Fundamental Data by TradingView

News

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Globe Newswire NAARDEN, the Netherlands and MIAMI, Sept. 06, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or NewAmsterdam or the Company ), a late-stage, clinical biopharmaceutical...\n more…

Wolverine Asset Management LLC Has $298,000 Position in NewAmsterdam Pharma (NASDAQ:NAMS)
Wolverine Asset Management LLC Has $298,000 Position in NewAmsterdam Pharma (NASDAQ:NAMS)

Zolmax Wolverine Asset Management LLC lifted its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 117.7% in the 2nd quarter, according to the company in its most recent filing with the...\n more…

NewAmsterdam Pharma (NASDAQ:NAMS) Receives Outperform Rating from Royal Bank of Canada
NewAmsterdam Pharma (NASDAQ:NAMS) Receives Outperform Rating from Royal Bank of Canada

Zolmax Royal Bank of Canada reissued their outperform rating on shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in a research note released on Thursday morning, Benzinga reports. Royal Bank of...\n more…

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September

Globe Newswire NAARDEN, The Netherlands and MIAMI, Aug. 30, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or NewAmsterdam or the Company ), a late-stage, clinical biopharmaceutical...\n more…

NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Up to $16.77
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Up to $16.77

Ticker Report NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) shares gapped up prior to trading on Wednesday . The stock had previously closed at $16.77, but opened at $17.15. NewAmsterdam Pharma shares last...\n more…

NewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated by Analysts at Needham & Company LLC
NewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated by Analysts at Needham & Company LLC

Zolmax Stock analysts at Needham Company LLC started coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) in a note issued to investors on Wednesday, MarketBeat reports. The firm...\n more…